Intrinsic Bioprobes Inc. Enters into a $1.27M Contract with the National Cancer Institute to Develop Multiplex Mass Spectrometric Immunoassays for Detection of Low Abundance Cancer-Related Proteins
Published: Mar 31, 2009
TEMPE, Ariz., March 31 /PRNewswire/ -- Intrinsic Bioprobes, Inc. today announced the start of a contract with the National Cancer Institute to develop effective technologies for accurate measurement of cancer-related proteins and peptides that improve diagnostic capabilities by effectively discerning diseased from non-diseased states. The total cost of the two-and-a-half-year contract is $1,276,360, out of which $1,130,272 is Federal money provided by the NCI, and $146,088 is the contractor's share provided by Intrinsic Bioprobes, Inc. This contract is in support of NCI's Clinical Proteomic Technologies for Cancer initiative to assess and apply proteomic technologies and data resources to solve critical problems in cancer research (http://proteomics.cancer.gov).
"The purpose of this contract is to stimulate the development of multiplex mass spectrometric immunoassay for the detection of low abundance cancer-related proteins/peptides from bodily fluids," says Dobrin Nedelkov, Ph.D., the Scientific Director of Intrinsic Bioprobes. "The application of proteomics tools in the clinical setting lags far behind their use in basic science and drug discovery. The multiplex mass spectrometric immunoassays will bridge that gap because they are highly specific and selective, have ultra-sensitive detection capabilities and broad dynamic range, and require limited sample preparation. The mass spectrometric aspect of the assays also enables single-step detection of protein isoforms and their individual quantification, which is an important protein diversity aspect regularly overlooked in contemporary proteomics approaches," adds Nedelkov.
Intrinsic Bioprobes, Inc. is a privately held Biotechnology Company focused on developing mass spectrometry-based assays and platforms for rapid and sensitive protein biomarker analysis. The company's proprietary technologies consist of Mass Spectrometric Immunoassay, a high-performance immunoassay combining micro-scale immunoaffinity capture and mass spectrometry for high-throughput analysis of proteins from complex biological matrices, and Bioreactive Mass Spectrometer Probes, devices for rapid, sensitive and accurate protein characterization. These root technologies are incorporated into the MASSAY System, a high-throughput mass spectrometry platform for rapid proteome analysis. For more information about Intrinsic Bioprobes, Inc., please visit http://www.intrinsicbio.com.
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
CONTACT: Intrinsic Bioprobes, Inc., +1-480-804-1778, firstname.lastname@example.org
Web site: http://www.intrinsicbio.com/